Apogee to Report 52-Week Phase 2 Data for Zumilokibart in Atopic Dermatitis Today

Overview

• Apogee Therapeutics will disclose Part A 52-week results from the Phase 2 APEX trial of zumilokibart (APG777) in patients with moderate-to-severe atopic dermatitis on March 23, 2026.
• A live conference call and webcast start at 8:00 a.m. ET, with access via the Investors section of Apogee’s website and a replay available after the event.
• The update represents a key clinical milestone for Apogee’s lead program in a large, underpenetrated inflammatory and immunology market.
• Zumilokibart is initially being developed for atopic dermatitis and is also in development for asthma and eosinophilic esophagitis.
• Apogee, a Nasdaq-listed clinical-stage biotech (APGE), applies advanced antibody engineering across four validated targets to pursue best-in-class efficacy and dosing.